Cytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023
20 Julho 2023 - 6:26PM
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, today announced it will report financial results
for the second quarter 2023 after market close on Tuesday, August
8th, 2023. The company’s management will webcast a corresponding
conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m.
Eastern Time to discuss its results, business developments and
outlook.
Live audio of the webcast will be available on the “Investors”
section of the company website at investors.cytekbio.com.
About Cytek BiosciencesCytek Biosciences
(Nasdaq: CTKB) is a leading cell analysis solutions company
advancing the next generation of cell analysis tools by delivering
high-resolution, high-content and high-sensitivity cell analysis
utilizing its patented Full Spectrum Profiling™ (FSP™) technology.
Cytek’s novel approach harnesses the power of information within
the entire spectrum of a fluorescent signal to achieve a higher
level of multiplexing with precision and sensitivity. Cytek’s FSP
platform includes its core instruments, the Aurora and Northern
Lights™ systems; its cell sorter, the Aurora CS; the flow cytometer
and imaging products under the Amnis® and Guava® brands; and
reagents, software and services to provide a comprehensive and
integrated suite of solutions for its customers. Cytek is
headquartered in Fremont, California with offices and distribution
channels across the globe. More information about the company and
its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system and certain
reagents for use therewith, which are available for clinical use in
countries where the regulatory approval has been obtained from the
local regulatory authorities, including China and the European
Union, Cytek’s products are for research use only and not for use
in diagnostic procedures. Please contact your local sales
representatives for the status of local regulatory approval.
Cytek, Full Spectrum Profiling, FSP, Northern Lights, Amnis and
Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page
and corporate Twitter account as channels of distribution of
information about its company, products, planned financial and
other announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed
material information and Cytek may use these channels to comply
with its disclosure obligations under Regulation FD. Therefore,
investors should monitor Cytek’s website, LinkedIn page, and
Twitter account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Media Contact:Stephanie OlsenLages &
Associates(949) 453-8080stephanie@lages.com
Investor Relations Contact:Paul D. GoodsonHead
of Investor Relationspgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024